The Ibrance Simulator is a Promotion resource, used by Pfizer Oncology Healthcare Development Managers, that will be used in Ibrance Promotional conversations.
Discrete event simulation is an effective form of scenario generation and engagement around service transformation for healthcare. It can be used to model hospital departments, pathways or entire health economies in an animated and compelling manner.
Simulations are communication tools. They open debate, they enable conversations and engender close working with hospitals and wider healthcare commissioning towards all round healthcare improvements.
The objective of the Ibrance simulation model is to demonstrate, to NHS stakeholders, the benefits of adopting Ibrance for the treatment of ER +ve, HER2 -ve patients with advanced breast cancer in the following key points:
Firstly the freeing of capacity in the chemotherapy clinic and cost savings by adopting Ibrance to delay disease progression and chemotherapy treatment.
Secondly, further Service optimisation by moving away from a consultant led or secondary care led service where appropriate.
The results from all scenarios can be exported into a results summary and, on request, the Results Summary Document and Data Analytics resource, can be provided to Healthcare Professions (HCPs) directly from the resource.
HowcouldIBRANCE make a difference to your service capacity and Optimisation ?
Ever wondered how you can discuss smoking cessation in a COPD consultation? Or what does a brief consultation on smoking cessation look like? These webinars bring solutions to these two challenges, to life.
This 3 minute animation video which provides an overview of the PALOMA-1 trial consisting of information such as study design, efficacy and quality of life (QoL). Once you have viewed the video and if you require further information please select the relevant tabs.
1. Dr Sandy Gupta and Bernadette Downey discuss the ‘deadly duo’ of smoking and cardiovascular disease and the health benefits of smoking cessation. They also highlight their experiences of the changing environment of smoking cessation services and re-enforce the need for a whole system approach across primary and secondary care.
1. GP Stephen Gaduzo and Smoking Cessation Advisor Lisa Fendall discuss how smoking is a significant cause of long term diseases such as COPD, cardiovascular disease and diabetes and the substantial health benefits of quitting smoking for these patient groups.
Dr Shobit Baijal explores the use of real world data to understand, in further detail, the use of Xalkori® in patients with ALK+ advanced NSCLC. He illustrates this by talking through a number of real world, retrospective, cohort study data that provides findings in support of sequential therapy with Xalkori®.
After highlighting how lung cancer biopsy reports have changed dramatically within 10 years, Prof. John Gosney delves into our understanding behind the ALK gene and the gold-standard method to detect the ALK gene rearrangement.
Erling Thor Donnelly, PhD. Pfizer | Oncology Lead, Sweden & Nordics IBRANCE Collaboration Lead
Ibrance is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:1
• In combination with an aromatase inhibitor;
• In combination with fulvestrant in women who have received prior endocrine therapy.
In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."
